Immunome
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Washington, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
18702 North Creek Pkwy Ste 100, Bothell,...Phone Number
(425) 939-7410Website
www.immunome.comRevenue
<$5 MillionStock Symbol
IMNMIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Immunome
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease.Explore more
Immunome Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunome your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Immunome, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Immunome has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Immunome has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Immunome
Product Launch: Get notified when Immunome launches new products
Earning: See what the market has to say on Immunome recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Immunome had a recent Job posting/layoffs
Check out if Immunome is spiking on competitors!
Recommended Actions
Find VP level buyers at Immunome
Find more new buyers
Compare Similar Companies to Immunome
Compare insights from companies similar to Immunome, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Immunome is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Immunome is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Immunome.
Immunome financials insights
Gather financial insights about Immunome, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Debt
$846K
2014
Debt
$892K
2015
Private Equity
$3.6M
2016
Series A
$5M
2020
Debt
$350K
Stock Offering
$39M
2021
Share Placement
$27M
2023
Share Placement
$124.7M
Immunome Tech Stack
A closer look at the technologies used by Immunome
Most Recent Scoops
Open Position
Open Position
Open Position
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Open Position
Immunome News & Media
What This Immunome Sale Means a Day Before a Big FDA Milestone
Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Immunome, Inc. (IMNM) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 10:40 AM EDTCompany ParticipantsMax Rosett - Chief Financial...Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development
Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc. (NASDAQ:IMNM) CEO and Chairman Clay Siegall reiterated heightened focus on building an oncology-focused pipeline centered on cell-surface-targeting agents and small molecules. The ultimate goal is to develop a targeted oncology platform for small molecules that can […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunome
Sign Up For FreeTo access detailed company insights
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome's pro... Read More
